Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000282836 represents a non-coding RNA transcript characterized as a "novel transcript, antisense to CCDC150". As an antisense RNA (natural antisense transcript; NAT), it is transcribed in the opposite direction to the CCDC150 gene. Such antisense transcripts can regulate their corresponding sense genes through diverse post-transcriptional mechanisms, including transcriptional interference, chromatin remodeling, RNA masking, and the generation of double-stranded RNA, thereby modulating gene expression at multiple levels. However, there is no evidence that ENSG00000282836 acts as a therapeutic target (such as a receptor, enzyme, transporter), nor are there any known drugs or biomarkers directly associated with this transcript. Its functional impact, if any, would relate to gene expression control rather than direct protein-coding activity[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CCDC150 (ENSG00000282836).